Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Inclusion Criteria: * Diagnosis of NB as defined by international criteria, i.e., histopathology (confirmed by the MSKCC Department of Pathology) or bone marrow metastases plus high urine catecholamine levels * High-risk NB as defined by risk-related treatment guidelines and the International NB Staging System,57 i.e., stage 4 with (any age) or without (\>365 days of age) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), or MYCN-amplified stage 4S. * Patients must have a history of tumor progression or persistent disease or failure to achieve complete response following standard therapy. * Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive MIBG or PET scans) or measurable (CT, MRI) disease documented after completion of prior systemic therapy. * Disease staging approximately within one month of treatment. * Human anti-mouse antibody (HAMA) titer \<1000 Elisa units/ml if applicable * Available autologous stem cells: ≥2 x 106 CD34+ cells/kg * Adequate cardiac function as measured by echocardiogram * Eligible NK donor * Signed informed consent indicating awareness of the investigational nature of this program. Donor Eligibility * Donor is blood-related and HLA-haploidentical to the recipient. * Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors. Tests include but are not limited to: HepBsAg, HepBsAb, HepBcAb, HepC antibody, HIV, HTLV I and II, VZV, CMV and VDRL, West Nile Virus and Chagas screen. Donor must have normal negative test results for HIV, HTLV I and II, and West Nile Virus. Donor exposure to other viral pathogens will be discussed on a case-by-case basis by the investigators. * Donor must be able to undergo leukopheresis for total volume of 10-15 liters. * There is no age restriction for the donor. Exclusion Criteria: * Patients with CR/VGPR disease * Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity \> or = to grade 3 except for hearing loss, alopecia, anorexia, nausea, hyperbilirubinemia and hypomagnesemia from TPN, which may be grade 3 * ANC should be \>500/uL; platelet count \>25K/uL. * History of allergy to mouse proteins * Active life-threatening infection * HAMA titer \>1000 Elisa units/ml * Inability to comply with protocol requirements Donor Exclusion Criteria * Cardiac risk factors precluding ability to undergo leukopheresis * Concurrent malignancy or autoimmune disease * Donor is pregnant.